Literature DB >> 9291299

Summary of antibody workshop: The Role of Humoral Immunity in the Treatment and Prevention of Emerging and Extant Infectious Diseases.

R M Krause1, N J Dimmock, D M Morens.   

Abstract

In the era before antibiotics, human diseases were commonly treated with immune animal and human sera, often with life-saving results. With the advent of emerging infectious diseases, many of which cannot be adequately treated or prevented, attempts to develop antibody treatments have taken on new importance. The role of humoral immunity in treatment and prevention was the focus of discussion at a 1996 workshop. The cellular and molecular mechanisms of neutralization were examined in detail. It was noted that success in passive immunity has frequently been the key element in devising a successful strategy to develop a vaccine for active immunization. The workshop concluded on a cautious note of optimism that antibody-based treatment and prevention for diseases such as human immunodeficiency virus infection, Ebola fever, and others of clinical and public health importance deserve further development and clinical trial.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9291299     DOI: 10.1086/514074

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

1.  Antibodies to rotavirus outer capsid glycoprotein VP7 neutralize infectivity by inhibiting virion decapsidation.

Authors:  Juan Ernesto Ludert; Marie Christine Ruiz; Carlos Hidalgo; Ferdinando Liprandi
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

Review 2.  Back to the future: antibody-based strategies for the treatment of infectious diseases.

Authors:  H Barbaros Oral; Cüneyt Ozakin; Cezmi A Akdiş
Journal:  Mol Biotechnol       Date:  2002-07       Impact factor: 2.695

Review 3.  Hendra and nipah infection: pathology, models and potential therapies.

Authors:  Frederic Vigant; Benhur Lee
Journal:  Infect Disord Drug Targets       Date:  2011-06

4.  Treatment of mice with human monoclonal antibody 24h after lethal aerosol challenge with virulent Venezuelan equine encephalitis virus prevents disease but not infection.

Authors:  Ann R Hunt; Richard A Bowen; Shana Frederickson; Toshiaki Maruyama; John T Roehrig; Carol D Blair
Journal:  Virology       Date:  2011-04-13       Impact factor: 3.616

Review 5.  Intranasal antibody prophylaxis for protection against viral disease.

Authors:  R Weltzin; T P Monath
Journal:  Clin Microbiol Rev       Date:  1999-07       Impact factor: 26.132

6.  Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis.

Authors:  S Hemachandra; K Kamboj; J Copfer; G Pier; L L Green; J R Schreiber
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

7.  Therapeutic passive vaccination against chronic Lyme disease in mice.

Authors:  W Zhong; T Stehle; C Museteanu; A Siebers; L Gern; M Kramer; R Wallich; M M Simon
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

8.  Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.

Authors:  Melissa D Simek; Wasima Rida; Frances H Priddy; Pham Pung; Emily Carrow; Dagna S Laufer; Jennifer K Lehrman; Mark Boaz; Tony Tarragona-Fiol; George Miiro; Josephine Birungi; Anton Pozniak; Dale A McPhee; Olivier Manigart; Etienne Karita; André Inwoley; Walter Jaoko; Jack Dehovitz; Linda-Gail Bekker; Punnee Pitisuttithum; Robert Paris; Laura M Walker; Pascal Poignard; Terri Wrin; Patricia E Fast; Dennis R Burton; Wayne C Koff
Journal:  J Virol       Date:  2009-05-13       Impact factor: 5.103

9.  Immune complexes stimulate CCR7-dependent dendritic cell migration to lymph nodes.

Authors:  Menna R Clatworthy; Caren E Petrie Aronin; Rebeccah J Mathews; Nicole Y Morgan; Kenneth G C Smith; Ronald N Germain
Journal:  Nat Med       Date:  2014-11-10       Impact factor: 53.440

10.  The Pathogenic Potential of a Microbe.

Authors:  Arturo Casadevall
Journal:  mSphere       Date:  2017-02-22       Impact factor: 4.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.